Furthermore, our results illustrated that potentiation of GLP-1 bioactivity suppressed this neuroinflammatory pathway, indicating a potentially novel mechanism of action for incretin-based therapies, which are promising treatment options for cognitive decline in patient with Alzheimer’s disease and type 2 diabetes mellitus. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.